This week was a busy and active week within the stem cell industry, as evidenced by our coverage of stem cell markets below. I am excited to share with you.
Check it out and let me know what you think?
Your Global Leader in Stem Cell Market Research
Acquisition further develops integrated cell therapy and regenerative medicine offering to enable development and patient access to innovative life-saving therapies
CHALFONT ST GILES, England; July 13, 2016 09:00 AM EST —(BUSINESS WIRE)–GE Healthcare has acquired Biosafe Group SA, a supplier of integrated cell bioprocessing systems for the rapidly growing cell therapy and regenerative medicine industry for an undisclosed sum. The acquisition of Biosafe expands GE Healthcare’s end-to-end ecosystem of products, solutions and services for our cell therapy customers, and expands GE’s technology reach to a number of new cell and therapy types. [Read more…]
Canada Prime Minister Justin Trudeau places emphasis on biological approaches being the future of medicine as he broadcasts government funding for establishment of the Center for Advanced Therapeutic Cell Technologies. See video of his announcement and key points below!
Key Points Include:
Want to be better informed than your competition? Get future stem cell industry updates.
BioInformant is the only research firm that has served the stem cell sector since it emerged. Our management team comes from a BioInformatics background – the science of collecting and analyzing complex genetic codes – and applies these techniques to the field of market research. BioInformant research has been cited by major news outlets that include the Wall Street Journal, Nature Biotechnology, CBS News, Medical Ethics, and the Center for BioNetworking. Serving Fortune 500 leaders that include GE Healthcare, Pfizer, Goldman Sachs, and Becton Dickinson, BioInformant is your global leader in stem cell industry data.
Click here to view our global strategic reports for the stem cell and cord blood industry.
July 14, 2015, COLOGNE, Germany—Axiogenesis AG, a leading supplier of tissue-specific human cell types derived from induced pluripotent stem cells (iPSCs), and provider of pre-clinical drug development assays and disease models, announced today that it has signed an sublicense agreement with GE Healthcare (GEHC). Under the agreement, GEHC will sublicense intellectual property to use human iPSCs, enabling Axiogenesis to develop cellular assays and models derived from stem cells for use in drug discovery and toxicity screening for its customers. This agreement strengthens Axiogenesis’ ability to offer the market freedom-to-operate with Axiogenesis’ proprietary iPSC-derived cells and tissues.
[Read more…]